by Peter Ciszewski | Oct 11, 2022
Bernd Kasper, MD, PhD, University of Heidelberg, Mannheim Cancer Center, Mannheim, Germany and Principal Investigator of the phase 3 DeFi clinical trial, discusses the impressive results of the trial, which evaluated nirogacestat in the treatment of desmoid...
by Peter Ciszewski | Oct 10, 2022
Olaf Bodamer, MD, PhD, Associate Chief of Genetics and Genomics at Boston Children’s Hospital, discusses his background. As Dr. Bodamer explains, he started his career as a pediatrician, specializing in metabolism. His interest in genetic metabolic...
by Peter Ciszewski | Oct 6, 2022
Kathie Bishop, PhD, Chief Scientific Officer, Acadia Pharmaceuticals, describes the mechanism of action of trofinetide, an orphan drug in development to treat Rett syndrome, which was recently assigned a PDUFA date of March 12, 2023. Rett syndrome is a rare...
by Peter Ciszewski | Oct 5, 2022
Pamela Bush, PhD, of Predictive Oncology talks about the company’s technology to use artificial intelligence (AI) to develop cancer medications. As Dr. Bush notes, a proof of concept study demonstrated that the company’s PeDAL platform can predict a tumor’s...
by Peter Ciszewski | Oct 4, 2022
Alan M. Mendelsohn, MD, Executive Vice President and Chief Medical Officer at Timber Pharmaceuticals, discusses the positive clinical data from the completed phase 2b CONTROL study of TMB-001, an investigational treatment for congenital ichthyosis. These data...
